How could China's new draft proposal benefit foreign companies?

12 April 2017

About a month ago, the Chinese Food and Drug Administration (CFDA) issued a draft proposal about easing the process for imported drugs to get into China, ie, ‘amended management for imported drugs registration.’

Ten days later, it gave the nod to AstraZeneca’s (LSE: AZN) lung cancer drug Tagrisso (osimertinib), reports The Pharma Letter’s local correspondent Wang Fangqing.

The sign is clear - China wants more imported drugs to meet the unmet needs in the domestic market. The dramatic move from the previous time-consuming procedures immediately stirred hot discussions in China’s pharma industry. Recently in Shanghai, senior managers from multinationals, venture capitals, contract research organizations and startups held an internal meeting to collect ideas to submit to the CFDA before April 21, the deadline for public opinions on the draft.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK